More US FDA Departures: ODE II Director Rosebraugh, GI Division Director Griebel to Retire
FDA will have three leadership positions vacant in the Office of Drug Evaluation II when Curtis Rosebraugh leaves at the end of the month.
You may also be interested in...
The move means Hylton Joffe can focus exclusively on his role as director of the Office of Rare Diseases.
Office of New Drug's chief of staff will become Amgen's director of global regulatory policy and R&D.
Dara Corrigan will become Fresenius-Kabi’s VP for global affairs and policy.